Brainsway files for $30m Nasdaq offering

Nasdaq Photo: Reuters
Nasdaq Photo: Reuters

The company has developed a magnetic helmet for treatment of neurological diseases.

Israeli medical devices company Brainsway Ltd. (TASE:BRIN) has filed a public prospectus for a Nasdaq offering to raise at least $30 million. Companies listed on the Tel Aviv Stock Exchange (TASE) usually raise capital at the same value at which they are traded in Israel. Brainsway's market cap is NIS 357 million, but the company's share price fell 3% today, following the announcement of the prospectus.

Brainsway has developed and markets a magnetic helmet for treatment of neurological diseases using magnetic stimulation of the brain's interior. The product was approved for marketing, and has been sold for a number of years for treatment of depression. Last year, it was also approved for treatment of obsessive compulsive disorder (OCD).

The current US government shutdown is preventing stock exchange offerings there, because offerings require approval by the US Securities and Exchange Commission (SEC), a government agency. At the same time, the company can begin its roadshow 15 days after the prospectus is filed, and if the shutdown ends during this period, the company's plan will not be delayed.

The company can make its offering according to its reports for the third quarter of 2018 until February 11. If it has not done so by that date, it can revise its prospectus to include its results for the fourth quarter and the full year and make its offering according to the revised prospectus. Late January is an opportune time for offerings by health companies, so it is worthwhile for Brainsway to submit its prospectus now in order to take advantage of the opportunity if the shutdown ends. This was also the preference of Anchiano Therapeutics Ltd. (TASE: ANCN) (formerly BioCanCell), which submitted its prospectus two weeks ago, and probably also Itamar Medical Ltd. (TASE:ITMR), which recently announced that it was preparing for an offering in the US.

Second attempt at US offering

Brainsway, which has been listed on the TASE since 2010, tried to hold an offering in the US in 2011, but withdrew the plan after failing to obtain the market value it sought. The previous attempt was before the company had made any sales and under different management. In retrospect, it appears that this decision was correct. After 2011, Brainsway obtained marketing approval for its product and tried to penetrate the US market, but had trouble initially, replaced several managers and business models, and began to achieve commercial success only recently (according to its reports). It was probably better for the company to experience these problems when it was traded in the Israeli capital market and to tackle the US market in a more mature state. Brainsway currently has $10 million in cash and burns $1 million a quarter, so that if the current state of the market prevents the company from carrying out its offering, it will be able to carry on in the local market.

Brainsway posted $11.62 million in revenue in the first nine months of 2018, 54% more than in the corresponding period in 2017. This increase is attributable to a change in business model led by CEO Yaacov Michlin, who took up his position in early 2017. Michlin switched Brainsway from the sale of machines, which generates immediate revenue, to a model based primarily on leasing systems and regular usage fees, which generates less revenue in the short term, but more in the long term. After a period of declining revenue after the new model was implemented, revenue began rising and exceeded its level before the change. Brainsway now also has a higher backlog of expected revenue.

Brainsway's gross profit margin was 78% in both the third quarter and first nine months of 2018. The company is still posting an operating loss, but this fell from $1.2 million in the third quarter of 2017 to $900,000 in the third quarter of 2018, and from $4.5 million in the first nine months of 2017 to $3.4 million in the first nine months of 2018. The company's net loss in the first nine months of 2018 was $4.3 million, compared with $4.2 million in the corresponding period in 2017, and its net loss fell from $1.8 million in the third quarter of 2017 to $1.4 million in the third quarter of 2018.

In addition to its activity in treatment of depression and OCD, Brainsway is also developing its product in a number of other brain indications, and is currently conducting a trial of the helmet in helping smokers to stop smoking.

Published by Globes, Israel business news - en.globes.co.il - on January 15, 2019

© Copyright of Globes Publisher Itonut (1983) Ltd. 2019

Nasdaq Photo: Reuters
Nasdaq Photo: Reuters
Work on the Green Line credit: Bar Lavi Egged wins tender to operate TA light rail Purple, Green Lines

NTA awarded the tender to Egged, which already operates the Red Line, despite government ministry opposition to one operator for the entire network.

David Amsalem  credit  Noam Moskowitz, Knesset Spokesperson's Office Rafael to pay state NIS 444m dividend

The minister in charge of the Government Companies Authority, David Amsalem, has approved the payment by the defense company.

Barak MX air defense system  credit: IAI IAI profit jumps 55%

Israel Aerospace Industries posted a net profit of $493 million for 2024, and ended the year with an all-time high orders backlog of $25 billion.

Amnon Shashua and Aviram Ziv credit: Eyal Izhar OrCam stymied by investor dispute with Shashua

Demands by institutional investors are blocking the visual and hearing impairment device developer's recovery plan.

A TSG system in tactical use  credit: PR TSG signs cooperation agreement with US defense co

The agreement includes the integration of TSG's advanced technologies into sensor-based defense systems, which will be integrated into the operational systems of US defense units.

Bria CEO Yair Adato credit: Kseniia Poliak Israeli visual generative AI co Bria raises $40m

Bria’s Visual Generative AI platform empowers businesses to create predictable, controllable, and on-brand content that aligns with their visual language.

Thu: TA 35 rises despite banks' weakness

Teva and Elbit Systems both rose strongly today.

El Al almost quintuples profit

The airline posted a net profit of $545 million for 2024, 4.7 times the profit in 2023, and an all-time high.

First International Bank of Israel CEO Eli Cohen  credit: Eyal Toueg First Int'l posts top return on equity

First International Bank of Israel's return on equity in 2024 was 19%, the highest among Israel's banks.

Matrix IT CEO Moti Gutman  credit: Idan Gross Matrix CEO Gutman among highest paid execs at TASE cos

Moti Gutman's total compensation cost in 2024 was NIS 23.7 million. Matrix posted 14.4% growth in operating profit.

Matrix Hq in Kfar Saba credit: Matrix Matrix to buy Magic in major Israeli IT merger

Magic will become wholly owned by Matrix in a triangular reverse merger. The combined company is expected to have a market cap of NIS 7.7 billion.

Bank Hapoalim branch  credit: Aviv Gottlieb Bank Hapoalim raising NIS 3b

The bank is offering two series of CoCo bonds, one of which is for 25 years, and 12-month commercial paper.

Ronit Harel Ben Zeev credit: Osnat Rom S&P Maalot Israel CEO: Capital market needs more women

Ronit Harel Ben Zeev talks to "Globes" about she came to work at the Tel Aviv Stock Exchange, the Israeli economy and S&P Maalot.

Finance Minister Bezalel Smotrich credit: GPO Yossi Zamir Israel's fiscal deficit narrows for fifth straight month

Record tax revenues and lower government spending due to the ceasefire and restrictions until the 2025 budget is passed have improved the fiscal deficit.

Ben Gurion Airport  credit: Shutterstock Ukraine war refugees skew Israel's migration figures

Many who left Israel in 2023 were recent arrivals from Ukraine and Russia - but even without them there was a large exit of the young and educated.

Bank of Israel credit: Shutterstock Israel's forex reserves jumped in February

Israel’s foreign exchange reserves at the end of February 2025 rose to $220.253 billion, an increase of $4.185 billion from their level at the end of January, the Bank of Israel reports.

Haifa Port  credit: Shlomi Yosef How Trump tariffs could benefit Israel

Israel's free trade agreement with the US makes it an attractive investment destination for companies seeking to preserve access to the US market.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018